Mirum Pharmaceuticals, Inc. (MIRM)
93.48
+0.99 (1.07%)
Upcoming Events
Latest Headlines
Mirum and Incyte to present zilurgisertib study results at ENDO 2026
June 4, 2026 8:06 AM - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 4, 2026 8:05 AM - BizWire
Form 4 Mirum Pharmaceuticals, For: Jun 01 Filed by: Peetz Christopher
June 2, 2026 7:50 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: May 29 Filed by: Cardon Lon
June 2, 2026 7:50 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: May 29 Filed by: Fischer Laurent
June 2, 2026 7:50 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: May 29 Filed by: Walbert Timothy P
June 2, 2026 7:50 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: May 29 Filed by: Ramasastry Saira
June 2, 2026 7:50 PM - SEC Filing
Citi Starts Mirum Pharmaceuticals (MIRM) at Buy
June 2, 2026 5:01 AM - StreetInsider
Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher
June 1, 2026 5:33 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Ramasastry Saira
June 1, 2026 4:05 PM - SEC Filing
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
June 1, 2026 4:43 AM - StreetInsider
Mirum presents new data on rare liver disease treatments at EASL congress
June 1, 2026 2:53 AM - StreetInsider
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
May 30, 2026 12:00 PM - BizWire
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
May 21, 2026 8:05 AM - BizWire
JPMorgan Reinstates Mirum Pharmaceuticals (MIRM) at Overweight
May 20, 2026 4:31 AM - StreetInsider
Wolfe Research Starts Mirum Pharmaceuticals (MIRM) at Outperform
May 19, 2026 5:32 AM - StreetInsider
Form 4 Mirum Pharmaceuticals, For: May 15 Filed by: Ramasastry Saira
May 18, 2026 8:33 PM - SEC Filing
Form 8-K Mirum Pharmaceuticals, For: May 12
May 18, 2026 4:06 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Ramasastry Saira
May 15, 2026 4:13 PM - SEC Filing
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026 4:01 PM - BizWire
Mirum Pharmaceuticals prices $600 million convertible notes offering
May 12, 2026 11:56 PM - StreetInsider
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
May 12, 2026 11:56 PM - BizWire
Mirum announces $600 million convertible notes offering due 2032
May 12, 2026 4:01 PM - StreetInsider
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
May 12, 2026 4:01 PM - BizWire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026 8:00 AM - BizWire
Mirum Pharmaceuticals (MIRM) PT Raised to $185 at H.C. Wainwright
May 8, 2026 7:00 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $145 at TD Cowen
May 7, 2026 8:50 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $142 at RBC Capital
May 7, 2026 8:30 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $136 at Stifel
May 7, 2026 7:31 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $129 at Baird
May 7, 2026 4:28 AM - StreetInsider
Mirum Pharmaceuticals, Inc. (MIRM) Misses Q1 EPS by 1309c ; Offers Guidance
May 6, 2026 4:20 PM - StreetInsider
Form 10-Q Mirum Pharmaceuticals, For: Mar 31
May 6, 2026 4:08 PM - SEC Filing
Form 8-K Mirum Pharmaceuticals, For: May 06
May 6, 2026 4:05 PM - SEC Filing
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026 4:01 PM - BizWire
Mirum Pharmaceuticals (MIRM) PT Raised to $140 at Morgan Stanley
May 5, 2026 8:01 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $175 at H.C. Wainwright
May 5, 2026 7:33 AM - StreetInsider
Baird Reiterates Outperform Rating on Mirum Pharmaceuticals (MIRM)
May 4, 2026 9:41 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $135 at Evercore ISI
May 4, 2026 8:45 AM - StreetInsider
Mirum reports volixibat meets primary endpoint in cholangitis study
May 4, 2026 8:01 AM - StreetInsider
Form 8-K Mirum Pharmaceuticals, For: May 04
May 4, 2026 8:00 AM - SEC Filing
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
May 4, 2026 8:00 AM - BizWire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
May 3, 2026 5:00 PM - BizWire
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
April 29, 2026 4:01 PM - BizWire
Mirum Pharmaceuticals (MIRM) PT Raised to $130 at Stifel
April 28, 2026 5:05 PM - StreetInsider
Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: BlackRock, Inc.
April 27, 2026 4:14 PM - SEC Filing
Mirum Pharmaceuticals (MIRM) PT Raised to $112 at Baird
April 27, 2026 11:21 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) PT Raised to $150 at H.C. Wainwright
April 27, 2026 10:02 AM - StreetInsider
Form 8-K Mirum Pharmaceuticals, For: Apr 27
April 27, 2026 8:08 AM - SEC Filing
MIRUM meets primary endpoint in hepatitis delta drug trial
April 27, 2026 8:00 AM - StreetInsider
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
April 27, 2026 8:00 AM - BizWire
Form ARS Mirum Pharmaceuticals, For: Dec 31
April 24, 2026 9:58 AM - SEC Filing
Form DEF 14A Mirum Pharmaceuticals, For: Dec 31
April 23, 2026 7:21 PM - SEC Filing
Form DEFA14A Mirum Pharmaceuticals,
April 23, 2026 7:21 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Apr 15 Filed by: Ramasastry Saira
April 16, 2026 8:40 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Ramasastry Saira
April 15, 2026 4:12 PM - SEC Filing
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2026 4:01 PM - BizWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) Reiterated at Overweight by Cantor Fitzgerald
April 10, 2026 8:01 AM - StreetInsider
Form 8-K/A Mirum Pharmaceuticals, For: Jan 23
April 8, 2026 4:14 PM - SEC Filing
Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: VANGUARD GROUP INC
March 27, 2026 10:53 AM - SEC Filing
Mirum Pharmaceuticals (MIRM) PT Raised to $125 at TD Cowen
March 27, 2026 6:24 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
March 26, 2026 4:41 AM - StreetInsider
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens
March 23, 2026 8:12 AM - StreetInsider
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Quan Joanne
March 17, 2026 7:30 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Radovich Peter
March 17, 2026 7:30 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: BJERKHOLT ERIC
March 17, 2026 7:30 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Mar 16 Filed by: Ramasastry Saira
March 17, 2026 7:30 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Peetz Christopher
March 17, 2026 7:30 PM - SEC Filing
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Howe Jolanda
March 17, 2026 7:30 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC
March 17, 2026 7:03 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Quan Joanne
March 17, 2026 7:01 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Radovich Peter
March 17, 2026 6:58 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
March 17, 2026 6:55 PM - SEC Filing
Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher
March 17, 2026 6:50 PM - SEC Filing
Citizens Reiterates Market Outperform Rating on Mirum Pharmaceuticals (MIRM)
March 17, 2026 5:30 AM - StreetInsider
Form 144 Mirum Pharmaceuticals, Filed by: Ramasastry Saira
March 16, 2026 4:06 PM - SEC Filing
Mirum Pharmaceuticals completes enrollment in liver disease drug study
March 16, 2026 8:00 AM - StreetInsider
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
March 16, 2026 8:00 AM - BizWire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2026 5:30 PM - BizWire
Form 4 Mirum Pharmaceuticals, For: Mar 06 Filed by: Radovich Peter
March 11, 2026 4:06 PM - SEC Filing
Full Article List